Janus Henderson Group PLC Buys New Stake in Erasca, Inc. $ERAS

Janus Henderson Group PLC purchased a new position in shares of Erasca, Inc. (NASDAQ:ERAS) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 3,710,966 shares of the company’s stock, valued at approximately $59,988,000.

Several other large investors have also recently added to or reduced their stakes in the stock. Spruce Street Capital LP purchased a new position in Erasca in the fourth quarter valued at about $14,469,000. Commodore Capital LP purchased a new stake in shares of Erasca in the first quarter worth about $51,372,000. Vivo Capital LLC grew its stake in shares of Erasca by 37.2% in the third quarter. Vivo Capital LLC now owns 9,273,428 shares of the company’s stock valued at $20,216,000 after buying an additional 2,516,672 shares in the last quarter. Siren L.L.C. grew its stake in shares of Erasca by 28.4% in the first quarter. Siren L.L.C. now owns 11,244,246 shares of the company’s stock valued at $181,932,000 after buying an additional 2,486,997 shares in the last quarter. Finally, State Street Corp grew its stake in shares of Erasca by 53.2% in the fourth quarter. State Street Corp now owns 6,174,642 shares of the company’s stock valued at $22,970,000 after buying an additional 2,145,386 shares in the last quarter. 67.78% of the stock is currently owned by institutional investors and hedge funds.

Erasca News Roundup

Here are the key news stories impacting Erasca this week:

• Neutral Sentiment: Multiple law firms reminded investors that August 10, 2026 is the deadline to seek appointment as lead plaintiff in a securities class action covering purchases of Erasca shares from January 14, 2025, through April 26, 2026. These announcements are largely investor-solicitation notices rather than separate new lawsuits. Bronstein Gewirtz Grossman class action announcement
• Negative Sentiment: The pending class action alleges that Erasca and certain senior executives misled investors about ERAS-0015’s competitive advantages, safety profile and intellectual-property protection. The allegations reportedly include claims that investors were given an overly favorable view of the program while the company raised approximately $258.8 million. Hagens Berman Erasca investigation
• Negative Sentiment: The litigation creates legal, financial and reputational risks for Erasca (ERAS), while potentially increasing investor uncertainty around ERAS-0015’s development prospects and commercial opportunity. The provided reports do not indicate a new company response or court finding, and the allegations have not been proven. Hagens Berman patent and safety risks announcement

Wall Street Analyst Weigh In

ERAS has been the topic of several recent research reports. HSBC set a $20.00 price target on Erasca in a research report on Tuesday, July 14th. Mizuho lowered their price objective on shares of Erasca from $28.00 to $26.00 and set an “outperform” rating for the company in a research report on Tuesday, May 12th. Stifel Nicolaus lifted their price objective on shares of Erasca from $20.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, April 27th. HC Wainwright reiterated a “buy” rating on shares of Erasca in a research note on Tuesday, July 14th. Finally, Wolfe Research set a $16.00 target price on shares of Erasca in a research report on Thursday, June 4th. Eight equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Erasca has a consensus rating of “Moderate Buy” and an average price target of $21.64.

Erasca Price Performance

Shares of Erasca stock opened at $18.15 on Friday. Erasca, Inc. has a 1-year low of $1.33 and a 1-year high of $24.28. The company has a market capitalization of $5.64 billion, a PE ratio of -19.52 and a beta of 0.66. The business has a 50-day moving average of $16.18 and a 200-day moving average of $14.38.

Erasca (NASDAQ:ERAS) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.48). On average, equities analysts expect that Erasca, Inc. will post -0.54 earnings per share for the current fiscal year.

About Erasca

Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.